Challenges in anticoagulation for patients with brain tumors

Area of Science:

• Neuro-oncology
• Hematology
• Clinical Pharmacology

Background:

• Venous thromboembolism (VTE) is a frequent complication in patients diagnosed with primary or metastatic brain cancer.
• Managing thrombosis in these patients requires balancing treatment efficacy against the risk of intracranial hemorrhage (ICH).

Purpose of the Study:

• To review current data on anticoagulant and antiplatelet therapies in brain tumor patients.
• To assess the risk of ICH associated with anticoagulation in primary versus metastatic brain tumors.
• To discuss emerging treatments like direct-acting oral anticoagulants and management strategies post-ICH.

Main Methods:

• Systematic review of cohort studies assessing ICH risk in patients with primary and metastatic brain tumors on anticoagulation.
• Analysis of data on warfarin, low-molecular-weight heparin, and direct-acting oral anticoagulants.
• Inclusion of data on inferior vena cava filters and anticoagulation resumption after ICH.

Main Results:

• Anticoagulation with warfarin or low-molecular-weight heparin significantly elevates ICH risk in primary brain cancer patients.
• Therapeutic anticoagulation does not appear to increase ICH risk in patients with metastatic brain tumors.
• Emerging data on direct-acting oral anticoagulants and other management strategies are summarized.

Conclusions:

• The risk-benefit profile of anticoagulation differs significantly between primary and metastatic brain tumors.
• Careful consideration of anticoagulation is crucial for brain tumor patients, with distinct approaches for different tumor types.
• Further research into novel anticoagulants and management protocols is warranted.